1380389-33-2

Basic information

• Product Name: 4-BroMo-2-Methoxy-3,5-diMethylpyridine
• Synonyms: 4-BroMo-2-Methoxy-3,5-diMethylpyridine;Pyridine, 4-bromo-2-methoxy-3,5-dimethyl-
• CAS NO: 1380389-33-2
• Molecular Formula: C8H10BrNO
• Molecular Weight: 216.0751
• Mol File: 1380389-33-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 247.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.390±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.23±0.10(Predicted)
• CAS DataBase Reference: 4-BroMo-2-Methoxy-3,5-diMethylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-2-Methoxy-3,5-diMethylpyridine(1380389-33-2)
• EPA Substance Registry System: 4-BroMo-2-Methoxy-3,5-diMethylpyridine(1380389-33-2)

Safety Data

• Hazardous Substances Data: 1380389-33-2(Hazardous Substances Data)

Upstream product

• 1429510-61-1 2-methoxy-3,5-dimethylpyridine-4-amine 
• 1393563-12-6 3,5-dibromo-2-methoxypyridin-4-amine 
• 20265-39-8 4-amino-2-methoxypyridine 
• 3718-65-8 3,5-Dimethylpyridine N-oxide 
• 70564-92-0 4-bromo-3,5-dimethyl-pyridine 1-oxide 
• 1380389-34-3 4-bromo-3,5-dimethyl-pyridin-2-ol 
• 74-88-4 methyl iodide 

Relevant articles and documents

FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES

The present invention discloses compounds formula (I): (I) wherein X is CH; The present compounds of formula (I) are dihydroorotate dehydrogenase (DHODH) inhibitors, and are useful for the treatment of inflammatory disorders, autoimmune disorders and cancer, such as e.g. lymphomas, leukemias, carcinomas, and sarcomas. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 60 to 136; examples 1 to 39; tables 1 and 2). An exemplary compound is e.g. : 4-ethyl-1-(7-fluoro-4-isopropyl-2- (2-methoxyphenyl)quinolin-6-yl)-3-(hydroxymethyl)-1H-1,2,4- triazol-5(4H)-one (example 1): (AA)

PYRAZOLOQUINOLINE DERIVATIVES

A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.

INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.